Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
UTRECHT, The Netherlands, March 09, 2016 -- Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, announced today that the United States Patent and Trademark Office (USPTO) has issued three patents related to the generation of bispecific antibodies and to high-throughput functional screening methods of large collections of bispecific antibodies.
The patents include claims covering the efficient formation of bispecific antibodies in individual cells, which supports the Company’s industry-scale manufacturing using the standard processes that are also used for the production of conventional monoclonal antibodies. Furthermore, the issued patents cover methods used by Merus to identify lead candidates with multiple mechanisms of action that have the potential to effectively kill tumor cells with high potency. This is an important step in the identification of lead bispecific antibody candidates with functionalities that compare favorably against other forms of immunotherapeutics, such as conventional monoclonal antibodies as well as their combinations. The issued patents include U.S. Patent No. 9,145,588, U.S. Patent No. 9,248,181 and U.S. Patent No. 9,248,182 and are expected to expire no earlier than between 2032 and 2033.
“These patents expand and strengthen our intellectual property portfolio and further reinforce our unique position in the bispecific antibody space,” said Ton Logtenberg, Ph.D., Chief Executive Officer of Merus. “Our Biclonics® technology platform, which retains the Immunoglobulin G format of conventional monoclonal antibodies, is the discovery engine for our pipeline of bispecific antibody candidates. The patents cover both our methods for the discovery of lead bispecific antibody candidates in cell-based functional assays as well as our clinical and commercial scale production. We continue to methodically and strategically expand our intellectual property estate around this technology platform as well as around our growing portfolio of immuno-oncology therapeutic candidates.”
About Merus B.V.
Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, referred to as Biclonics. Biclonics are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have several of the same features of conventional monoclonal antibodies, such as long half-life and low immunogenicity. Merus’ lead bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial in Europe as a potential treatment for HER2-expressing solid tumors. Merus’ second bispecific antibody candidate, MCLA-117, is being developed as a potential treatment for acute myeloid leukemia. The Company also has a pipeline of proprietary bispecific antibody candidates in preclinical development, including Biclonics designed to bind to various combinations of immunomodulatory molecules, including PD-1 and PD-L1.
Contacts: Merus B.V. Shelley Margetson – [email protected] +31 (0)30 253 8800 Argot Partners Eliza Schleifstein – [email protected] 1-917-763-8106
